CG
IBRX icon

Cutler Group’s ImmunityBio IBRX Stock Holding History

Cutler Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,800
Closed -$1K – 4222
2022
Q4 		$1K Sell
8,800
-2,200
-20% -$12.1K ﹤0.01% 4040
2022
Q3 		$4K Buy
11,000
+3,800
+53% +$17.3K ﹤0.01% 3790
2022
Q2 		$1K Buy
+7,200
New +$28.9K ﹤0.01% 4611
2021
Q2 		– Sell
-8,600
Closed -$15K – 5975
2021
Q1 		$15K Buy
8,600
+3,500
+69% +$90.7K ﹤0.01% 3444
2020
Q4 		$3K Buy
5,100
+200
+4% +$1.92K ﹤0.01% 3960
2020
Q3 		$2K Sell
4,900
-2,800
-36% -$27.9K ﹤0.01% 4046
2020
Q2 		$36K Buy
+7,700
New +$43.5K ﹤0.01% 1982
2017
Q4 		– Sell
-3,300
Closed -$4K – 5317
2017
Q3 		$4K Sell
3,300
-2,300
-41% -$14.2K ﹤0.01% 4576
2017
Q2 		$14K Buy
+5,600
New +$24.2K ﹤0.01% 3798
2016
Q4 		– Sell
-13,800
Closed -$5K – 6848
2016
Q3 		$5K Sell
13,800
-37,300
-73% -$279K ﹤0.01% 4942
2016
Q2 		$30K Buy
+51,100
New +$397K ﹤0.01% 2918
2016
Q1 		– Sell
-4,700
Closed -$2K – 6786
2015
Q4 		$2K Buy
+4,700
New +$69.7K ﹤0.01% 5557

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's IBRX Position: Q1 2024 in Review

Cutler Group sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 86 shares.

Cutler Group first reported a position in IBRX in Q4 2015 and held it in 23 quarters. The position peaked at $246K in Q4 2020. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

  • Cutler Group reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 86 ImmunityBio shares in Q1 2024.
  • Cutler Group first reported a position in ImmunityBio in Q4 2015 and held it in 23 quarters.
  • Cutler Group's ImmunityBio position peaked at $246K in Q4 2020.
  • 165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.